sur MAAT PHARMA (isin : FR0012634822)
MaaT Pharma successfully completes a fundraising of 19.2 million euros
MaaT Pharma, based in Lyon, announces the successful finalization of its global offer reaching 19.2 million euros. This operation included the sale of 2,273,704 new ordinary shares at 8 euros per unit, in the context of a reserved offer and a public offer. The majority of funds came from the offer reserved for institutional investors, generating €17.3 million, while individual investors contributed €0.9 million via the PrimaryBid platform.
The capital raised will finance the completion of phase 3 clinical trials for their product MaaT013, essential in the treatment of acute graft-versus-host disease, as well as the development of their portfolio. The company plans to use these funds to expand other clinical trials across Europe and prepare for a phase 3 trial in the United States.
At the same time, Seventure Partners, one of the shareholders, sold 125,000 existing shares for one million euros. MaaT Pharma also uses this financing to cover working capital requirements and the repayment of current debts.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MAAT PHARMA